24/7 Market News Snapshot 03 September, 2024 – Elevai Labs, Inc. Common Stock (NASDAQ:ELAB)

September 3, 2024

DENVER, Colo., 03 September, 2024 (247marketnews.com) – (NASDAQ:ELAB) are discussed in this article.
Elevai Labs, Inc. is currently experiencing a positive upward trajectory in pre-market trading, with shares priced at $0.316, representing an impressive gain of 18.62% from the previous day’s close of $0.266. This significant increase is accompanied by robust trading activity, totaling 14.65 million shares, signaling heightened investor interest and momentum in the company. Such a pronounced rise in demand suggests growing confidence among investors, potentially fueled by recent developments and announcements from the firm.

In a noteworthy advancement, Elevai Labs has released promising results from a collaborative research study with Carly Klein, President of the National Hair Loss Medical Aesthetics (NHLMA), which investigates the effectiveness of Elevai Exosomes™ in addressing hair thinning and inflammation. The study’s innovative treatment protocol involved in-office scalp microneedling followed by the application of Elevai empower™, a proprietary topical exosome serum, along with the at-home use of Elevai enfinity™, another specialized exosome product. Over a 12-month period, participants reported significant improvements, including the cessation of crown inflammation, reversal of miniaturizing hairs, and the reawakening of dormant hair follicles.

Carly Klein commented on the encouraging findings, noting that their study specifically tested patients with androgenetic alopecia and utilized Elevai’s age zero exosomes directly on the scalp. The promising results highlight the potential of this technology to enhance current hair restoration practices.

In line with these findings, Elevai is moving forward with additional research initiatives focused on its upcoming Elevai S-Series Root Renewal System™, an innovative three-part regimen designed to elevate hair and scalp wellness. Dr. Jordan R. Plews, CEO of Elevai Skincare Inc., emphasized the importance of these developments, affirming the company’s dedication to advancing exosome technology in the realm of hair and scalp health. As Elevai Labs continues to pioneer innovative solutions, the firm remains poised to impact the evolving landscape of medical aesthetics and biopharmaceuticals significantly.

Related news for (ELAB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.